Insite Vision Inc (INSV) 0.1400 $INSV
InSite Vision Reports First Quarter 2015 Financial Results
Business Wire - Tue May 12, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended March 31, 2015. Revenues for the quarter ended March 31, 2015 were $3.4 million compared to $1.2 million for the same period in 2014; increase in revenues was due to a $3.0 million upfront license payment. Net loss for the quarter ended March 31, 2015 was $0.8 million, or $0.01 per share, compared to a net loss of $4.7 million, or $0.04 per share, in 2014. As of March 31, 2015, cash and cash equivalents totaled $1.1 million.
InSite Vision to Report First Quarter 2015 Results on May 14, 2015
Business Wire - Thu May 07, 7:35AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the first quarter ended March 31, 2015 on Thursday, May 14, 2015.
InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical, Inc.
Business Wire - Tue Mar 17, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today announced that it, along with other plaintiffs, has entered into a settlement agreement to dismiss a patent infringement lawsuit against Mylan Pharmaceutical, Inc. concerning Mylan's Abbreviated New Drug Application (ANDA) seeking marketing approval from the U.S. Food and Drug Administration of a 1% azithromycin ophthalmic solution before the expiration of the patents protecting AzaSite.
AKRX: 42.47 (+0.97)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.43 (+0.10), AGN: 240.22 (+2.88), ACAD: 40.31 (+1.14), ITEK: 5.85 (+0.05), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), FOMX: 11.36 (-0.05), AERI: 11.22 (-0.04), CBMG: 29.54 (+2.04)
Blepharitis Therapeutics Pipeline Review 2015 - 4 Companies & 6 Drug Profiles
M2 - Mon Mar 02, 6:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/jpl728/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Foamix Pharmaceuticals Ltd. - InSite Vision Incorporated - Laboratoires Thea S.A. - Novaliq GmbH Drug Profiles - (azithromycin dexamethasone) - azithromycin - dexamethasone - ISV-405 - minocycline Gel - Nov-137 For more information visit http://www.researchandmarkets.com/research/jp...lepharitis
FOMX: 11.36 (-0.05)
InSite Vision's (INSV) CEO Timothy Ruane on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 17, 8:50PM CST
InSite Vision Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Tue Feb 17, 3:00PM CST
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter and year ended December 31, 2014. The Company reported net income for the years ended 2014 and 2013 of $26.8 million, or $0.20 per share, in 2014 and $5.8 million, or $0.04 per share, in 2013. Driving profitability in 2014 was a $36.0 million gain on the extinguishment of the AzaSite Notes in June 2014. In 2013, revenues included $15.5 million from the sale of rights to receive royalties on the net sales of Besivance(R) and $10.5 million in minimum royalties on AzaSite(R).
InSite Vision to Report Fourth Quarter and Year-End 2014 Results on February 17, 2015
Business Wire - Tue Feb 10, 3:05PM CST
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the fourth quarter and year ended December 31, 2014 on Tuesday, February 17, 2015.
InSite Vision Announces License Agreement for AzaSite(R), AzaSite Xtra(TM) and BromSite(TM) in Europe, Middle East and Africa
Business Wire - Mon Feb 02, 7:30AM CST
InSite Vision Incorporated (OTCBB:INSV) today announced that it has entered into a license agreement with Nicox S.A. (NYSE Euronext Paris: COX), a France-based publicly traded company, for the development and commercialization of InSite's innovative ophthalmic therapeutic products AzaSite (1% azithromycin), AzaSite Xtra (2% azithromycin) and BromSite (0.075% bromfenac) all formulated in InSite's DuraSite(R) drug delivery system. The agreement grants Nicox exclusive rights to commercialize all three products in Europe (including Eastern Europe), Middle East and Africa (EMEA). Nicox expects to file European Marketing Authorizations (MAAs) for AzaSite and BromSite by first quarter 2016 with first commercial launch in late 2017.
Nicox signs exclusive license agreement with InSite Vision for AzaSite(R) and BromSite(TM) in Europe
GlobeNewswire - Mon Feb 02, 12:41AM CST
-- InSite grants Nicox exclusive license for AzaSite(R) (1% azithromycin), BromSite(TM) (0.075% bromfenac) and AzaSite Xtra(TM) (2% azithromycin) in Europe, Middle East and Africa
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 6.42 (+0.21), ITEK: 5.85 (+0.05), NBS: 2.37 (-0.01), FOMX: 11.36 (-0.05), AERI: 11.22 (-0.04), OCUL: 26.43 (+0.16), AGN: 240.22 (+2.88), CANF: 2.43 (+0.10), ACAD: 40.31 (+1.14), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), TEVA: 60.19 (-0.04), OHRP: 2.77 (+0.04), CBMG: 29.54 (+2.04)
Stemline Therapeutics (STML) Crumbles: Stock Falls by 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 7:44AM CST
Stemline Therapeutics (STML) fell nearly 10% in the last trading session amid huge volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
STML: 13.42 (-0.01)
InSite Vision Announces Date for Annual Stockholder Meeting
Business Wire - Fri Dec 19, 3:30PM CST
InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company's 2015 Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Monday, March 31, 2015, for stockholders of record on February 5, 2015. The Annual Meeting will be held at InSite Vision's headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail notice of internet availability of the definitive proxy statement for the Annual Meeting and its annual report in February 2015.
Ocular Pain - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/vd2jg6/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bayer AG - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Sylentis S.A. For more information visit http://www.researchandmarkets.com/research/vd...cular_pain
Blepharitis Pipeline Market Review on Drugs and Companies H2 2014
PRWeb - Thu Nov 27, 9:30PM CST
The report "Blepharitis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. The report is built using data and information sourced databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Complete Report is Available @ http://www.rnrmarketresearch.com/blepharitis-...eport.html .
Cataract Therapeutic Pipeline Market Review by Companies and Drugs H2 2014 Report at RnRMarketResearch.com
PRWeb - Fri Nov 21, 7:31AM CST
The report "Cataract - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/cataract-pip...eport.html .
InSite Vision Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:03PM CST
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter ended September 30, 2014. Revenues for the third quarter of 2014 were $0.4 million compared to $5.3 million for the same period in 2013. In the third quarter of 2013, revenues included an additional $3.7 minimum royalty true-up payment for net sales of AzaSite(R). Net loss for the third quarter of 2014 was $3.3 million, or $0.02 per share, compared to net income of $0.6 million, or less than $0.01 per share, in the third quarter of 2013.
InSite Vision to Report Third Quarter 2014 Financial Results on November 5, 2014
Business Wire - Wed Oct 29, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the quarter ended September 30, 2014 on Wednesday, November 5, 2014.
Nanosphere (NSPH) Soars: Stock Adds 26.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:51AM CDT
Nanosphere, Inc. (NSPH) was a big mover last session, as its shares rose almost 27% on the day.
EBS: 30.91 (+0.19), FCSC: 3.92 (-0.10), NSPH: 3.80 (-0.15)
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 7:44AM CDT
Pluristem Therapeutics, Inc. (PSTI) was a big mover last session, as the company saw its shares rise over 7% on the day
CBM: 40.70 (+1.70), PSTI: 2.72 (+0.04), ONTY: 2.59 (+0.16)
InSite Vision Reports First Quarter 2015 Financial Results
Business Wire - Tue May 12, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended March 31, 2015. Revenues for the quarter ended March 31, 2015 were $3.4 million compared to $1.2 million for the same period in 2014; increase in revenues was due to a $3.0 million upfront license payment. Net loss for the quarter ended March 31, 2015 was $0.8 million, or $0.01 per share, compared to a net loss of $4.7 million, or $0.04 per share, in 2014. As of March 31, 2015, cash and cash equivalents totaled $1.1 million.
InSite Vision to Report First Quarter 2015 Results on May 14, 2015
Business Wire - Thu May 07, 7:35AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the first quarter ended March 31, 2015 on Thursday, May 14, 2015.
InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical, Inc.
Business Wire - Tue Mar 17, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today announced that it, along with other plaintiffs, has entered into a settlement agreement to dismiss a patent infringement lawsuit against Mylan Pharmaceutical, Inc. concerning Mylan's Abbreviated New Drug Application (ANDA) seeking marketing approval from the U.S. Food and Drug Administration of a 1% azithromycin ophthalmic solution before the expiration of the patents protecting AzaSite.
AKRX: 42.47 (+0.97)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.43 (+0.10), AGN: 240.22 (+2.88), ACAD: 40.31 (+1.14), ITEK: 5.85 (+0.05), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), FOMX: 11.36 (-0.05), AERI: 11.22 (-0.04), CBMG: 29.54 (+2.04)
Blepharitis Therapeutics Pipeline Review 2015 - 4 Companies & 6 Drug Profiles
M2 - Mon Mar 02, 6:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/jpl728/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Foamix Pharmaceuticals Ltd. - InSite Vision Incorporated - Laboratoires Thea S.A. - Novaliq GmbH Drug Profiles - (azithromycin dexamethasone) - azithromycin - dexamethasone - ISV-405 - minocycline Gel - Nov-137 For more information visit http://www.researchandmarkets.com/research/jp...lepharitis
FOMX: 11.36 (-0.05)
InSite Vision's (INSV) CEO Timothy Ruane on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 17, 8:50PM CST
InSite Vision Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Tue Feb 17, 3:00PM CST
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter and year ended December 31, 2014. The Company reported net income for the years ended 2014 and 2013 of $26.8 million, or $0.20 per share, in 2014 and $5.8 million, or $0.04 per share, in 2013. Driving profitability in 2014 was a $36.0 million gain on the extinguishment of the AzaSite Notes in June 2014. In 2013, revenues included $15.5 million from the sale of rights to receive royalties on the net sales of Besivance(R) and $10.5 million in minimum royalties on AzaSite(R).
InSite Vision to Report Fourth Quarter and Year-End 2014 Results on February 17, 2015
Business Wire - Tue Feb 10, 3:05PM CST
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the fourth quarter and year ended December 31, 2014 on Tuesday, February 17, 2015.
InSite Vision Announces License Agreement for AzaSite(R), AzaSite Xtra(TM) and BromSite(TM) in Europe, Middle East and Africa
Business Wire - Mon Feb 02, 7:30AM CST
InSite Vision Incorporated (OTCBB:INSV) today announced that it has entered into a license agreement with Nicox S.A. (NYSE Euronext Paris: COX), a France-based publicly traded company, for the development and commercialization of InSite's innovative ophthalmic therapeutic products AzaSite (1% azithromycin), AzaSite Xtra (2% azithromycin) and BromSite (0.075% bromfenac) all formulated in InSite's DuraSite(R) drug delivery system. The agreement grants Nicox exclusive rights to commercialize all three products in Europe (including Eastern Europe), Middle East and Africa (EMEA). Nicox expects to file European Marketing Authorizations (MAAs) for AzaSite and BromSite by first quarter 2016 with first commercial launch in late 2017.
Nicox signs exclusive license agreement with InSite Vision for AzaSite(R) and BromSite(TM) in Europe
GlobeNewswire - Mon Feb 02, 12:41AM CST
-- InSite grants Nicox exclusive license for AzaSite(R) (1% azithromycin), BromSite(TM) (0.075% bromfenac) and AzaSite Xtra(TM) (2% azithromycin) in Europe, Middle East and Africa
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 6.42 (+0.21), ITEK: 5.85 (+0.05), NBS: 2.37 (-0.01), FOMX: 11.36 (-0.05), AERI: 11.22 (-0.04), OCUL: 26.43 (+0.16), AGN: 240.22 (+2.88), CANF: 2.43 (+0.10), ACAD: 40.31 (+1.14), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), TEVA: 60.19 (-0.04), OHRP: 2.77 (+0.04), CBMG: 29.54 (+2.04)
Stemline Therapeutics (STML) Crumbles: Stock Falls by 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 7:44AM CST
Stemline Therapeutics (STML) fell nearly 10% in the last trading session amid huge volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
STML: 13.42 (-0.01)
InSite Vision Announces Date for Annual Stockholder Meeting
Business Wire - Fri Dec 19, 3:30PM CST
InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company's 2015 Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Monday, March 31, 2015, for stockholders of record on February 5, 2015. The Annual Meeting will be held at InSite Vision's headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail notice of internet availability of the definitive proxy statement for the Annual Meeting and its annual report in February 2015.
Ocular Pain - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/vd2jg6/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bayer AG - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Sylentis S.A. For more information visit http://www.researchandmarkets.com/research/vd...cular_pain
Blepharitis Pipeline Market Review on Drugs and Companies H2 2014
PRWeb - Thu Nov 27, 9:30PM CST
The report "Blepharitis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. The report is built using data and information sourced databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Complete Report is Available @ http://www.rnrmarketresearch.com/blepharitis-...eport.html .
Cataract Therapeutic Pipeline Market Review by Companies and Drugs H2 2014 Report at RnRMarketResearch.com
PRWeb - Fri Nov 21, 7:31AM CST
The report "Cataract - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/cataract-pip...eport.html .
InSite Vision Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:03PM CST
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter ended September 30, 2014. Revenues for the third quarter of 2014 were $0.4 million compared to $5.3 million for the same period in 2013. In the third quarter of 2013, revenues included an additional $3.7 minimum royalty true-up payment for net sales of AzaSite(R). Net loss for the third quarter of 2014 was $3.3 million, or $0.02 per share, compared to net income of $0.6 million, or less than $0.01 per share, in the third quarter of 2013.
InSite Vision to Report Third Quarter 2014 Financial Results on November 5, 2014
Business Wire - Wed Oct 29, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the quarter ended September 30, 2014 on Wednesday, November 5, 2014.
Nanosphere (NSPH) Soars: Stock Adds 26.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:51AM CDT
Nanosphere, Inc. (NSPH) was a big mover last session, as its shares rose almost 27% on the day.
EBS: 30.91 (+0.19), FCSC: 3.92 (-0.10), NSPH: 3.80 (-0.15)
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 7:44AM CDT
Pluristem Therapeutics, Inc. (PSTI) was a big mover last session, as the company saw its shares rise over 7% on the day
CBM: 40.70 (+1.70), PSTI: 2.72 (+0.04), ONTY: 2.59 (+0.16)
